<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998672</url>
  </required_header>
  <id_info>
    <org_study_id>PHS-Px-102-I-02</org_study_id>
    <nct_id>NCT01998672</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Oral Dose Phase I Study With Px-102</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Multiple Oral Doses of Px-102 to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenex Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenex Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of the FXR agonist Px-102&#xD;
      in healthy subjects after 7 days multiple oral dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-centre, double-blind, randomized, placebo-controlled, parallel group&#xD;
      phase I study with healthy male subjects receiving ascending multiple oral oral doses of&#xD;
      Px-102 to assess the safety and tolerability, pharmacokinetics and pharmacodynamics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Px-102</measure>
    <time_frame>7 days</time_frame>
    <description>Adverse event monitoring, laboratory values, cardiovascular monitoring. Comparison active vs. placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Px-102 and metabolites</measure>
    <time_frame>Day 1: 0 min, 15 min, 30 min, 60 min, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 12 h, 22 h, 24 h; Day 5 and 6: pre-dose; Day 7: 0 min, 15 min, 30 min, 60 min, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 12 h, 22 h, 24 h, 30 h.</time_frame>
    <description>Plasma, urine and fecal concentrations (ng/mL) of Px-102 and metabolites measured by LC-MS/MS. AUC, Cmax and other pk parameters. Comparison of the pk data on day 7 vs. day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8 and 10 hours after administration on Days 1 and 7; Pre-dose, 2 hours and 8 hours after administration on Days 2 to 6; at 22 hours after the last administration</time_frame>
    <description>Markers for FXR activation (e.G. FGF19 (pg/mL) measurement by ELISA). Comparison active vs. placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Px-102</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral drinking solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Px-102</intervention_name>
    <description>Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg</description>
    <arm_group_label>Px-102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drinking solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subject of Caucasian origin 18 to 45 years of age (inclusive).&#xD;
&#xD;
          -  Good state of health (mentally and physically) as determined by medical history,&#xD;
             physical examination, vital signs, ECG recording and clinical lab results.&#xD;
&#xD;
          -  BMI in between 20-29 kg/m² (inclusive); with absolute weight in between 70 to 120 kg.&#xD;
&#xD;
          -  Total cholesterol and liver enzyme levels [alanine aminotransferase (ALT), aspartate&#xD;
             aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (AP)]&#xD;
             strictly within the normal ranges at screening and on Day -1. Serum triglyceride not&#xD;
             exceeding the upper limit of normal range.&#xD;
&#xD;
          -  HbA1c ≤ 6.5%&#xD;
&#xD;
          -  Subject has been informed both verbally and in writing and has given written consent&#xD;
             to participation in the study prior to start and any study-related procedure.&#xD;
&#xD;
          -  Negative results for HIV- and Hepatitis-B and -C serology at screening.&#xD;
&#xD;
          -  Subject (including female partners of childbearing potential) has to use a highly&#xD;
             effective method of birth control (failure rate less than 1% per year when used&#xD;
             consistently and correctly), e.g. implants, injectables, combined oral contra-ceptives&#xD;
             in combination with a barrier method, some intrauterine contraceptive devices or&#xD;
             sexual abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs within 7 days (30 if the drug is a&#xD;
             possible enzyme inducer) prior to administration of study medication. Use of drugs&#xD;
             known to induce steatosis (e.g. valproate, amiodarone or prednisone) or to affect body&#xD;
             weight and carbohydrate metabolism&#xD;
&#xD;
          -  Any acute or chronic illness or clinically relevant finding at screening and at&#xD;
             base-line examination which may jeopardize the subject's participation in the study&#xD;
&#xD;
          -  History or presence of biliary obstruction or biliary disease, hepatic encephalopathy,&#xD;
             advanced ascites, portal hypertension, esophageal/gastric variceal bleeding,&#xD;
             hepatocellular carcinoma, previous liver transplantation or any other chronic liver&#xD;
             disease&#xD;
&#xD;
          -  Renal dysfunction, e.g. glomerular filtration rate ≤ 80 ml/min/1.73 m2 (as determined&#xD;
             by the formula of Cockroft-Gault)&#xD;
&#xD;
          -  Type I or II Diabetes&#xD;
&#xD;
          -  Any clinically relevant abnormality on screening medical assessment, laboratory&#xD;
             examination, 12-lead ECG&#xD;
&#xD;
          -  Any clinically relevant finding in the baseline telemetry within the pre-dose&#xD;
             evaluated observation period of at least 20 hours&#xD;
&#xD;
          -  Marked baseline prolongation of QT/QTc interval (QTc interval &gt; 440 ms) in the 12-lead&#xD;
             ECG using the Fridericia method for QTc analysis&#xD;
&#xD;
          -  Heart rate &lt; 50 bpm.&#xD;
&#xD;
          -  History of pathological cardiovascular symptoms or a severe cardiovascular event&#xD;
&#xD;
          -  History of severe chronic autoimmune diseases such as severe allergy, atopic eczema,&#xD;
             chronic dermatitis, severe psoriasis, multiple sclerosis, severe asthma, lupus or&#xD;
             related disorders&#xD;
&#xD;
          -  Allergies (except for mild forms of hay fever) or history of hypersensitivity&#xD;
             reactions&#xD;
&#xD;
          -  Smoking (regular or irregular) &gt; 5 cigarettes (or equivalent) per day&#xD;
&#xD;
          -  Excessive alcohol drinking (more than approximately 20 g alcohol per day), unable to&#xD;
             refrain from alcohol drinking from 48 hours prior to dosing until the last&#xD;
             pharmacokinetic blood sample has been withdrawn&#xD;
&#xD;
          -  Positive test for drugs or alcohol at screening or prior to the dosing session&#xD;
&#xD;
          -  History of alcoholism or drug/chemical/substance abuse within past 2 years&#xD;
&#xD;
          -  Investigator deems the subject unable or unwilling to comply fully with the study&#xD;
             protocol&#xD;
&#xD;
          -  Has received clinical study medication within the last 30 days prior to this study&#xD;
&#xD;
          -  Donation or loss of 400 ml or more of blood within eight (8) weeks prior to dosing&#xD;
&#xD;
          -  Allergic to any of the active or inactive ingredients in the study medication&#xD;
&#xD;
          -  Any other reason which the Investigator considers unsuitable for the subject to&#xD;
             participate&#xD;
&#xD;
          -  Any condition or previous disease leading to pruritus or itching of the skin.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Kremoser, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Phenex Pharmaceuticals AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FOCUS Clinical Drug Development GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

